(Abstracted from Cancer 2019;125:398–405)
More than 70% of patients diagnosed with endometrial cancer (EC) are stage I, and such early-stage disease has good outcomes, with reported 5-year survival rates of 90%. However, a small subgroup has been identified—the so-called high-intermediate–risk (HIR) EC—which has relatively high local and distant recurrence rates, resulting in poor survival.
Divisions of Gynecologic Oncology (F.J.B., J.H., C.M.C., D.E.C., P.J.G.) and Pathology (A.S.), Ohio State University Comprehensive Cancer Center, Columbus, OH